<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00360529</url>
  </required_header>
  <id_info>
    <org_study_id>511.71</org_study_id>
    <secondary_id>VIOLET</secondary_id>
    <nct_id>NCT00360529</nct_id>
  </id_info>
  <brief_title>24-week Placebo-controlled Trial of Flibanserin Once Daily in Premenopausal Women With Hypoactive Sexual Desire Disorder</brief_title>
  <official_title>A Twenty Four Week, Randomized, Double-Blind, Placebo-Controlled, Safety and Efficacy Trial of Flibanserin 50mg Every Evening and Flibanserin 100mg Every Evening in Women With Hypoactive Sexual Desire Disorder in North America</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sprout Pharmaceuticals, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sprout Pharmaceuticals, Inc</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is designed to assess the safety and efficacy of flibanserin in the treatment of
      premenopausal women with Hypoactive Sexual Desire Disorder (HSDD) that meets standard
      diagnostic criteria. Efficacy for flibanserin will be assessed vs. a parallel placebo group.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This trial was designed as a prospective, multicenter trial containing a 24-week, randomized,
      double blind, placebo controlled, parallel-group period that assessed the effects of
      flibanserin (maximum total daily dose: 100 mg q.d.) compared with placebo in premenopausal
      women with HSDD, determined by Diagnostic and Statistical Manual IV- Text Revision (DSM
      IV-TR®) criteria. Three hundred patients were to be randomized to each treatment group. This
      trial examined the safety and efficacy of flibanserin compared to placebo for 24 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2006</start_date>
  <completion_date type="Actual">April 2008</completion_date>
  <primary_completion_date type="Actual">April 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Satisfying Sexual Event Monthly Change From Baseline at Final Visit</measure>
    <time_frame>Baseline, Week 24</time_frame>
    <description>Change from baseline in the frequency of sexual satisfying events, as measured via e-Diary, standardized to a 28-day period. Change from baseline is calculated as the difference between the four week baseline period and Week 21 to Week 24.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sexual Desire Monthly Change on Electronic Diary From Baseline at Final Visit</measure>
    <time_frame>Baseline, Week 24</time_frame>
    <description>Change from baseline in eDiary Sexual Desire Monthly Total Score standardized to a 28-day period. Change from baseline calculated as the difference between the 4 week baseline period and Week 21 to Week 24. Patients recorded information daily throughout trial. Every time the eDiary was completed, a desire question was asked. If a patient did not complete the diary on a given day, the patient was not asked to enter desire information for more than a 24-hour retrospective period. The desire item read &quot;Indicate your most intense level of sexual desire in the last 24 hours/since your last visit.&quot; Potential responses included &quot;no,&quot; &quot;low,&quot; &quot;moderate,&quot; or &quot;strong&quot;, scored 0-3 (0 indicating no desire and 3 indicating the highest level of desire):
0 = No desire
= Low desire
= Moderate desire
= Strong desire
Total score ranged from 0-84, with higher scores reflecting stronger desire). Monthly desire score was calculated as 28 x (sum of daily desire scores/number of responses).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Female Sexual Distress Scale - Revised (FSDS-R) Total Score Change From Baseline at Final Visit</measure>
    <time_frame>Baseline, Week 24</time_frame>
    <description>Change from baseline in the Female Sexual Distress Scale - revised (FSDS-R) Total Score with a seven day recall period.
The FSDS is a measure of female personal distress associated with sexual dysfunction. Reliability and validity of the FSDS (12-item version) has been evaluated in different samples of sexually functional and dysfunctional women. An additional question (Question 13) was added to the validated FSDS© in order to capture distress related to specifically sexual desire so that this domain could be appropriately captured. FSDS plus Question 13 comprises FSDS-R, thus making the FSDS-R a self-administered 13 item questionnaire. The maximum total score of the FSDS-R is '52' (score of minimum of 0 and maximum of 4 for each item) and indicates the maximum level of sexual distress (the higher the score, the higher the level of reported sexual desire).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Female Sexual Distress Scale - Revised (FSDS-R) Question 13 Score Change From Baseline at Final Visit</measure>
    <time_frame>Baseline, Week 24</time_frame>
    <description>Change from baseline in the FSDS-R Question 13 (Bothered by low sexual desire). The FSDS is a measure of female personal distress associated with sexual dysfunction. Reliability and validity of the FSDS (12-item version) has been evaluated in different samples of sexually functional and dysfunctional women. An additional question (Question 13) was added to the validated FSDS© in order to capture distress related to specifically sexual desire so that this domain could be appropriately captured. FSDS plus Question 13 comprises FSDS-R, thus making the FSDS-R a self-administered 13 item questionnaire. The scoring for item 13 is from 0-4, with 4 indicating the highest level of sexual distress.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Female Sexual Functioning Index (FSFI) Desire Domain Score Change From Baseline at Final Visit</measure>
    <time_frame>Baseline, Week 24</time_frame>
    <description>Female Sexual Function Inventory (FSFI) Desire Domain assesses sexual desire or interest with 2 questions ranging from 1 (very low) to 5 (very high). The domain total score is multiplied by 0.6 yielding scores ranging from 1.2 to 6 (higher scores = higher level of desire or interest).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Female Sexual Functioning Index (FSFI) Total Score Change From Baseline at Final Visit</measure>
    <time_frame>Baseline, Week 24</time_frame>
    <description>The FSFI© is a self-administered questionnaire to assess FSD, which consists of 19 questions that are scored from '0' to '5.' The scale contains six domains: desire, arousal, lubrication, orgasm, satisfaction, and pain. Higher scores indicate higher levels of the domain assessed. The total score is a weighted average of the six domains, each contributing a maximum of 6 points to the total, so the minimum score is 2, while the maximum score of FSFI© is 36.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Benefit Evaluation</measure>
    <time_frame>Week 24</time_frame>
    <description>The Patient Benefit Evaluation is a single question asking the patient whether or not she experienced a meaningful benefit from the study medication during the trial. This question (&quot;Overall, do you believe that you have experienced a meaningful benefit from the study medication?&quot;) was asked upon treatment discontinuation.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">880</enrollment>
  <condition>Sexual Dysfunctions, Psychological</condition>
  <arm_group>
    <arm_group_label>fibanserin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>flibanserin 50 mg q.h.s.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>flibanserin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>flibanserin 100 mg q.h.s.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo q.h.s.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>flibanserin</intervention_name>
    <description>flibanserin placebo versus 50 mg qhs versus 100 mg qhs</description>
    <arm_group_label>fibanserin</arm_group_label>
    <arm_group_label>flibanserin</arm_group_label>
    <arm_group_label>placebo</arm_group_label>
    <other_name>flibanserin 50 mg</other_name>
    <other_name>flibanserin 100mg</other_name>
    <other_name>placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Women who are 18 years of age and older.

          2. Premenopausal women having regular menstrual periods who have HSDD (decreased sexual
             desire), generalized acquired type, according to DSM IV-TR criteria.

          3. Patient must meet minimum cut-off scores on questionnaires relating to sexual
             functioning and sexual distress.

          4. Patients must be willing to try to have sexual activity (e.g., any act involving
             direct genital stimulation) at least once monthly.

          5. Patients must be willing and able to use an electronic diary (eDiary) on a daily basis
             (e.g., have access to a working land line telephone for daily data transmissions).

          6. At the Baseline Visit, patients must have complied with eDiary use adequately.

          7. Patients must be in a stable, monogamous, heterosexual relationship that is secure and
             communicative, for at least 1 year prior to the Screen Visit. The partner is expected
             to be physically present at least 50% of each month.

          8. Patients must have used a medically acceptable method of contraception for at least 3
             months before the Baseline Visit (Visit 2) and continue to use that medically
             acceptable method of contraception during the trial.

          9. In the investigators opinion, patients must be reliable, honest, compliant, and agree
             to co-operate with all trial evaluations as well as to be able to perform them.

         10. Patients must be able and willing to give meaningful, written informed consent prior
             to participation in the trial, in accordance with regulatory requirements. Patients
             must have sufficient understanding to communicate effectively with the investigator,
             and be willing to discuss their sexual functioning with the investigative staff.

         11. Patients must have a clinically acceptable Pap smear as read by a cytology facility
             (no evidence of malignancy or squamous intraepithelial lesions) within 6 months before
             the Screen Visit.

        Exclusion Criteria:

          1. Patients who have taken any medication noted in the protocols List of Prohibited
             Medications within 30 days before screening.

          2. Patients whose sexual function was affected (enhanced or worsened) in the
             investigators opinion by any medication within 30 days before the Screen Visit and
             anytime prior to the Baseline Visit.

          3. Patients with a history of drug dependence or abuse within the past one year.

          4. Patients with a history of multiple severe reactions (i.e., allergic or
             oversensitivity to usual doses) to drugs that affect the brain.

          5. Patients with a history of participation in a trial of another investigational
             medication within one month prior to the Screen Visit, or participation in any
             previous clinical trial of flibanserin.

          6. Patients who meet accepted diagnostic criteria for sexual disorders that would
             interfere with improvement in HSDD (sexual aversion, substance-induced sexual
             problems, urge to live as a man, etc.

          7. Patients who indicate that their sexual partner has inadequately treated sexual
             problems that could interfere with the patients response to treatment.

          8. Patients who have entered the menopausal transition or menopause or have had a
             hysterectomy.

          9. Patients with findings at the Screen Visit of infection, inflammation, undue
             tenderness, or shrinkage (atrophy) of the female organs.

         10. Patients who are breast feeding or have breastfed within the last 6 months prior to
             the Baseline Visit.

         11. Patients who are pregnant or have been pregnant within the last 6 months prior to the
             Baseline Visit.

         12. Patients with a history of Major Depressive Disorder within 6 months prior the Screen
             Visit, a score indicating depression on a depression scale, a history of suicide
             attempt, or current suicidal ideation evident at the Screen or Baseline Visit.

         13. Patients with a history of any other psychiatric disorders that could impact sexual
             function, risks patients safety, or may impact compliance.

        &lt;truncated&gt;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sprout Pharmaceuticals</last_name>
    <role>Study Chair</role>
    <affiliation>Sprout Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>511.71.01034 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.71.01042 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>South Birmingham</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.71.01016 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.71.01041 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>La Mesa</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.71.01011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.71.01027 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Westlake Village</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.71.01035 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.71.01010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Groton</city>
        <state>Connecticut</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.71.01021 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>New Britain</city>
        <state>Connecticut</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.71.01037 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Newark</city>
        <state>Delaware</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.71.01001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Boynton Beach</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.71.01032 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.71.01014 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.71.01025 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pembroke Pines</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.71.01006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Plantation</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.71.01015 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.71.01038 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.71.01036 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.71.01029 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.71.01028 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Renton</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.71.01024 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>New Orlean</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.71.01040 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Towson</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.71.01045 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Brighton</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.71.01005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.71.01030 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.71.01012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.71.01007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.71.01023 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>New Bern</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.71.01002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.71.01044 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.71.01026 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.71.01039 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Edmond</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.71.01003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Danville</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.71.01033 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.71.01031 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.71.01022 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mt. Pleasant</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.71.01020 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Germantown</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.71.01017 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.71.01018 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.71.01008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Huntington</city>
        <state>West Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.71.02002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.71.02006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kelowna</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.71.02011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Surrey</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.71.02007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.71.02008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Victoria</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.71.02012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Victoria</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.71.02010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.71.02001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.71.02004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Burlington</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.71.02013 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.71.02009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Oshawa</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.71.02003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.71.02005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.71.02014 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Québec</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 3, 2006</study_first_submitted>
  <study_first_submitted_qc>August 3, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 4, 2006</study_first_posted>
  <results_first_submitted>March 14, 2012</results_first_submitted>
  <results_first_submitted_qc>June 6, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 27, 2016</results_first_posted>
  <last_update_submitted>June 6, 2016</last_update_submitted>
  <last_update_submitted_qc>June 6, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 27, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sexual Dysfunctions, Psychological</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>placebo at bedtime</description>
        </group>
        <group group_id="P2">
          <title>Flibanserin 50 mg q.h.s.</title>
          <description>Flibanserin 50 mg at bedtime</description>
        </group>
        <group group_id="P3">
          <title>Flibanserin 100 mg q.h.s</title>
          <description>Flibanserin 100 mg at bedtime</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="295"/>
                <participants group_id="P2" count="295"/>
                <participants group_id="P3" count="290"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="234"/>
                <participants group_id="P2" count="230"/>
                <participants group_id="P3" count="199"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="61"/>
                <participants group_id="P2" count="65"/>
                <participants group_id="P3" count="91"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="23"/>
                <participants group_id="P3" count="33"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="18"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Reason discontinued not explained above</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>placebo at bedtime</description>
        </group>
        <group group_id="B2">
          <title>Flibanserin 50 mg q.h.s.</title>
          <description>Flibanserin 50 mg at bedtime</description>
        </group>
        <group group_id="B3">
          <title>Flibanserin 100 mg q.h.s</title>
          <description>Flibanserin 100 mg at bedtime</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="295"/>
            <count group_id="B2" value="295"/>
            <count group_id="B3" value="290"/>
            <count group_id="B4" value="880"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35.5" spread="7.0"/>
                    <measurement group_id="B2" value="36.3" spread="7.5"/>
                    <measurement group_id="B3" value="35.6" spread="7.2"/>
                    <measurement group_id="B4" value="35.8" spread="7.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>18 - 34 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="126"/>
                    <measurement group_id="B2" value="127"/>
                    <measurement group_id="B3" value="134"/>
                    <measurement group_id="B4" value="387"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>35 - 44 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="136"/>
                    <measurement group_id="B2" value="125"/>
                    <measurement group_id="B3" value="118"/>
                    <measurement group_id="B4" value="379"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;= 45 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="38"/>
                    <measurement group_id="B4" value="114"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="295"/>
                    <measurement group_id="B2" value="295"/>
                    <measurement group_id="B3" value="290"/>
                    <measurement group_id="B4" value="880"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="235"/>
                    <measurement group_id="B2" value="237"/>
                    <measurement group_id="B3" value="229"/>
                    <measurement group_id="B4" value="701"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="35"/>
                    <measurement group_id="B4" value="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66"/>
                    <measurement group_id="B2" value="69"/>
                    <measurement group_id="B3" value="66"/>
                    <measurement group_id="B4" value="201"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="229"/>
                    <measurement group_id="B2" value="226"/>
                    <measurement group_id="B3" value="224"/>
                    <measurement group_id="B4" value="679"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Marital Status</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Unmarried</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58"/>
                    <measurement group_id="B2" value="81"/>
                    <measurement group_id="B3" value="61"/>
                    <measurement group_id="B4" value="200"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Married</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="237"/>
                    <measurement group_id="B2" value="214"/>
                    <measurement group_id="B3" value="229"/>
                    <measurement group_id="B4" value="680"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Education level</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Partial high school</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High school graduate or equivalent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="26"/>
                    <measurement group_id="B4" value="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Partial college/university</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="78"/>
                    <measurement group_id="B2" value="80"/>
                    <measurement group_id="B3" value="85"/>
                    <measurement group_id="B4" value="243"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>College/university graduate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="139"/>
                    <measurement group_id="B2" value="131"/>
                    <measurement group_id="B3" value="130"/>
                    <measurement group_id="B4" value="400"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-graduate/professional degree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="46"/>
                    <measurement group_id="B4" value="133"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Employment status</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Full time (&gt;= 40 hours/week)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="195"/>
                    <measurement group_id="B2" value="194"/>
                    <measurement group_id="B3" value="180"/>
                    <measurement group_id="B4" value="569"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Part time (17-39 hours/week)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54"/>
                    <measurement group_id="B2" value="58"/>
                    <measurement group_id="B3" value="48"/>
                    <measurement group_id="B4" value="160"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Occassional (1-16 hours/week)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Full time homemaker</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="31"/>
                    <measurement group_id="B4" value="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unemployed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>How long in present relationship</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10.39" spread="6.50"/>
                    <measurement group_id="B2" value="11.05" spread="6.94"/>
                    <measurement group_id="B3" value="10.48" spread="6.38"/>
                    <measurement group_id="B4" value="10.64" spread="6.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Alcohol status</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Non drinker</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68"/>
                    <measurement group_id="B2" value="83"/>
                    <measurement group_id="B3" value="78"/>
                    <measurement group_id="B4" value="229"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Drinks - no interference</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="227"/>
                    <measurement group_id="B2" value="212"/>
                    <measurement group_id="B3" value="212"/>
                    <measurement group_id="B4" value="651"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Drinks - possible interference</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Smoking history</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Never smoked</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="200"/>
                    <measurement group_id="B2" value="202"/>
                    <measurement group_id="B3" value="206"/>
                    <measurement group_id="B4" value="608"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ex-smoker</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                    <measurement group_id="B2" value="56"/>
                    <measurement group_id="B3" value="55"/>
                    <measurement group_id="B4" value="171"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Currently smokes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="29"/>
                    <measurement group_id="B4" value="101"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Smoking history - pack years</title>
          <units>pack years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.72" spread="7.27"/>
                    <measurement group_id="B2" value="6.46" spread="6.09"/>
                    <measurement group_id="B3" value="6.07" spread="8.26"/>
                    <measurement group_id="B4" value="6.43" spread="7.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kilograms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="71.09" spread="15.31"/>
                    <measurement group_id="B2" value="72.78" spread="17.05"/>
                    <measurement group_id="B3" value="74.19" spread="17.53"/>
                    <measurement group_id="B4" value="72.68" spread="16.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body mass index</title>
          <units>kilogram/square meter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.35" spread="6.07"/>
                    <measurement group_id="B2" value="26.90" spread="6.13"/>
                    <measurement group_id="B3" value="27.04" spread="5.85"/>
                    <measurement group_id="B4" value="26.76" spread="6.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Satisfying Sexual Event Monthly Change From Baseline at Final Visit</title>
        <description>Change from baseline in the frequency of sexual satisfying events, as measured via e-Diary, standardized to a 28-day period. Change from baseline is calculated as the difference between the four week baseline period and Week 21 to Week 24.</description>
        <time_frame>Baseline, Week 24</time_frame>
        <population>The Full Analysis Set (FAS) consisted of those patients who were randomized to a treatment group, received at least one dose of study medication, and had at least one on-treatment efficacy assessment. The FAS was analyzed for efficacy.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>placebo at bedtime</description>
          </group>
          <group group_id="O2">
            <title>Flibanserin 50 mg q.h.s.</title>
            <description>Flibanserin 50 mg at bedtime</description>
          </group>
          <group group_id="O3">
            <title>Flibanserin 100 mg q.h.s</title>
            <description>Flibanserin 100 mg at bedtime</description>
          </group>
        </group_list>
        <measure>
          <title>Satisfying Sexual Event Monthly Change From Baseline at Final Visit</title>
          <description>Change from baseline in the frequency of sexual satisfying events, as measured via e-Diary, standardized to a 28-day period. Change from baseline is calculated as the difference between the four week baseline period and Week 21 to Week 24.</description>
          <population>The Full Analysis Set (FAS) consisted of those patients who were randomized to a treatment group, received at least one dose of study medication, and had at least one on-treatment efficacy assessment. The FAS was analyzed for efficacy.</population>
          <units>number of events</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="285"/>
                <count group_id="O2" value="291"/>
                <count group_id="O3" value="275"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" spread="3.4"/>
                    <measurement group_id="O2" value="1.4" spread="3.6"/>
                    <measurement group_id="O3" value="1.6" spread="3.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Flibanserin 50 mg qhs versus placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0454</p_value>
            <p_value_desc>Hierarchical ordering used for multiple endpoints, and Hochberg used for multiple dose comparisons. P-values ordered (p1≤p2). If p2≤0.05 then all doses significant. If p1≤0.025 then reject null for p1</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Flibanserin 100 mg qhs versus placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0024</p_value>
            <p_value_desc>Hierarchical ordering used for multiple endpoints, and Hochberg used for multiple dose comparisons. P-values ordered (p1≤p2). If p2≤0.05 then all doses significant. If p1≤0.025 then reject null for p1</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Sexual Desire Monthly Change on Electronic Diary From Baseline at Final Visit</title>
        <description>Change from baseline in eDiary Sexual Desire Monthly Total Score standardized to a 28-day period. Change from baseline calculated as the difference between the 4 week baseline period and Week 21 to Week 24. Patients recorded information daily throughout trial. Every time the eDiary was completed, a desire question was asked. If a patient did not complete the diary on a given day, the patient was not asked to enter desire information for more than a 24-hour retrospective period. The desire item read &quot;Indicate your most intense level of sexual desire in the last 24 hours/since your last visit.” Potential responses included &quot;no,&quot; “low,” “moderate,” or “strong&quot;, scored 0-3 (0 indicating no desire and 3 indicating the highest level of desire):
0 = No desire
= Low desire
= Moderate desire
= Strong desire
Total score ranged from 0-84, with higher scores reflecting stronger desire). Monthly desire score was calculated as 28 x (sum of daily desire scores/number of responses).</description>
        <time_frame>Baseline, Week 24</time_frame>
        <population>The Full Analysis Set (FAS) consisted of those patients who were randomized to a treatment group, received at least one dose of study medication, and had at least one on-treatment efficacy assessment. The FAS was analyzed for efficacy.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>placebo at bedtime</description>
          </group>
          <group group_id="O2">
            <title>Flibanserin 50 mg q.h.s.</title>
            <description>Flibanserin 50 mg at bedtime</description>
          </group>
          <group group_id="O3">
            <title>Flibanserin 100 mg q.h.s</title>
            <description>Flibanserin 100 mg at bedtime</description>
          </group>
        </group_list>
        <measure>
          <title>Sexual Desire Monthly Change on Electronic Diary From Baseline at Final Visit</title>
          <description>Change from baseline in eDiary Sexual Desire Monthly Total Score standardized to a 28-day period. Change from baseline calculated as the difference between the 4 week baseline period and Week 21 to Week 24. Patients recorded information daily throughout trial. Every time the eDiary was completed, a desire question was asked. If a patient did not complete the diary on a given day, the patient was not asked to enter desire information for more than a 24-hour retrospective period. The desire item read &quot;Indicate your most intense level of sexual desire in the last 24 hours/since your last visit.” Potential responses included &quot;no,&quot; “low,” “moderate,” or “strong&quot;, scored 0-3 (0 indicating no desire and 3 indicating the highest level of desire):
0 = No desire
= Low desire
= Moderate desire
= Strong desire
Total score ranged from 0-84, with higher scores reflecting stronger desire). Monthly desire score was calculated as 28 x (sum of daily desire scores/number of responses).</description>
          <population>The Full Analysis Set (FAS) consisted of those patients who were randomized to a treatment group, received at least one dose of study medication, and had at least one on-treatment efficacy assessment. The FAS was analyzed for efficacy.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="285"/>
                <count group_id="O2" value="291"/>
                <count group_id="O3" value="275"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.9" spread="0.9"/>
                    <measurement group_id="O2" value="8.2" spread="0.9"/>
                    <measurement group_id="O3" value="9.1" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Flibanserin 50 mg qhs versus placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2606</p_value>
            <p_value_desc>Hierarchical ordering used for multiple endpoints, and Hochberg used for multiple dose comparisons. P-values ordered (p1≤p2). If p2≤0.05 then all doses significant. If p1≤0.025 then reject null for p1</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Model includes treatment, centre and baseline as a covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.0</ci_lower_limit>
            <ci_upper_limit>3.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Flibanserin 100 mg qhs versus placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.066</p_value>
            <method>ANCOVA</method>
            <method_desc>Model includes treatment, centre and baseline as a covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.1</ci_lower_limit>
            <ci_upper_limit>4.6</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Female Sexual Distress Scale - Revised (FSDS-R) Total Score Change From Baseline at Final Visit</title>
        <description>Change from baseline in the Female Sexual Distress Scale - revised (FSDS-R) Total Score with a seven day recall period.
The FSDS is a measure of female personal distress associated with sexual dysfunction. Reliability and validity of the FSDS (12-item version) has been evaluated in different samples of sexually functional and dysfunctional women. An additional question (Question 13) was added to the validated FSDS© in order to capture distress related to specifically sexual desire so that this domain could be appropriately captured. FSDS plus Question 13 comprises FSDS-R, thus making the FSDS-R a self-administered 13 item questionnaire. The maximum total score of the FSDS-R is ‘52’ (score of minimum of 0 and maximum of 4 for each item) and indicates the maximum level of sexual distress (the higher the score, the higher the level of reported sexual desire).</description>
        <time_frame>Baseline, Week 24</time_frame>
        <population>The Full Analysis Set (FAS) consisted of those patients who were randomized to a treatment group, received at least one dose of study medication, and had at least one on-treatment efficacy assessment. The FAS was analyzed for efficacy.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>placebo at bedtime</description>
          </group>
          <group group_id="O2">
            <title>Flibanserin 50 mg q.h.s.</title>
            <description>Flibanserin 50 mg at bedtime</description>
          </group>
          <group group_id="O3">
            <title>Flibanserin 100 mg q.h.s</title>
            <description>Flibanserin 100 mg at bedtime</description>
          </group>
        </group_list>
        <measure>
          <title>Female Sexual Distress Scale - Revised (FSDS-R) Total Score Change From Baseline at Final Visit</title>
          <description>Change from baseline in the Female Sexual Distress Scale - revised (FSDS-R) Total Score with a seven day recall period.
The FSDS is a measure of female personal distress associated with sexual dysfunction. Reliability and validity of the FSDS (12-item version) has been evaluated in different samples of sexually functional and dysfunctional women. An additional question (Question 13) was added to the validated FSDS© in order to capture distress related to specifically sexual desire so that this domain could be appropriately captured. FSDS plus Question 13 comprises FSDS-R, thus making the FSDS-R a self-administered 13 item questionnaire. The maximum total score of the FSDS-R is ‘52’ (score of minimum of 0 and maximum of 4 for each item) and indicates the maximum level of sexual distress (the higher the score, the higher the level of reported sexual desire).</description>
          <population>The Full Analysis Set (FAS) consisted of those patients who were randomized to a treatment group, received at least one dose of study medication, and had at least one on-treatment efficacy assessment. The FAS was analyzed for efficacy.</population>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="289"/>
                <count group_id="O2" value="293"/>
                <count group_id="O3" value="280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.9" spread="0.7"/>
                    <measurement group_id="O2" value="-6.1" spread="0.7"/>
                    <measurement group_id="O3" value="-8.9" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Flibanserin 50 mg qhs versus placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1601</p_value>
            <p_value_desc>Hierarchical ordering used for multiple endpoints, and Hochberg used for multiple dose comparisons. P-values ordered (p1≤p2). If p2≤0.05 then all doses significant. If p1≤0.025 then reject null for p1</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Model includes treatment, centre and baseline as a covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-2.9</ci_lower_limit>
            <ci_upper_limit>0.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Flibanserin 100 mg qhs versus placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0001</p_value>
            <p_value_desc>Hierarchical ordering used for multiple endpoints, and Hochberg used for multiple dose comparisons. P-values ordered (p1≤p2). If p2≤0.05 then all doses significant. If p1≤0.025 then reject null for p1</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Model includes treatment, centre and baseline as a covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-3.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-5.6</ci_lower_limit>
            <ci_upper_limit>-2.2</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Female Sexual Distress Scale - Revised (FSDS-R) Question 13 Score Change From Baseline at Final Visit</title>
        <description>Change from baseline in the FSDS-R Question 13 (Bothered by low sexual desire). The FSDS is a measure of female personal distress associated with sexual dysfunction. Reliability and validity of the FSDS (12-item version) has been evaluated in different samples of sexually functional and dysfunctional women. An additional question (Question 13) was added to the validated FSDS© in order to capture distress related to specifically sexual desire so that this domain could be appropriately captured. FSDS plus Question 13 comprises FSDS-R, thus making the FSDS-R a self-administered 13 item questionnaire. The scoring for item 13 is from 0-4, with 4 indicating the highest level of sexual distress.</description>
        <time_frame>Baseline, Week 24</time_frame>
        <population>The Full Analysis Set (FAS) consisted of those patients who were randomized to a treatment group, received at least one dose of study medication, and had at least one on-treatment efficacy assessment. The FAS was analyzed for efficacy.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>placebo at bedtime</description>
          </group>
          <group group_id="O2">
            <title>Flibanserin 50 mg q.h.s.</title>
            <description>Flibanserin 50 mg at bedtime</description>
          </group>
          <group group_id="O3">
            <title>Flibanserin 100 mg q.h.s</title>
            <description>Flibanserin 100 mg at bedtime</description>
          </group>
        </group_list>
        <measure>
          <title>Female Sexual Distress Scale - Revised (FSDS-R) Question 13 Score Change From Baseline at Final Visit</title>
          <description>Change from baseline in the FSDS-R Question 13 (Bothered by low sexual desire). The FSDS is a measure of female personal distress associated with sexual dysfunction. Reliability and validity of the FSDS (12-item version) has been evaluated in different samples of sexually functional and dysfunctional women. An additional question (Question 13) was added to the validated FSDS© in order to capture distress related to specifically sexual desire so that this domain could be appropriately captured. FSDS plus Question 13 comprises FSDS-R, thus making the FSDS-R a self-administered 13 item questionnaire. The scoring for item 13 is from 0-4, with 4 indicating the highest level of sexual distress.</description>
          <population>The Full Analysis Set (FAS) consisted of those patients who were randomized to a treatment group, received at least one dose of study medication, and had at least one on-treatment efficacy assessment. The FAS was analyzed for efficacy.</population>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="289"/>
                <count group_id="O2" value="293"/>
                <count group_id="O3" value="280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" spread="0.1"/>
                    <measurement group_id="O2" value="-0.6" spread="0.1"/>
                    <measurement group_id="O3" value="-0.8" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Flibanserin 50 mg qhs versus placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1144</p_value>
            <p_value_desc>Hierarchical ordering used for multiple endpoints, and Hochberg used for multiple dose comparisons. P-values ordered (p1≤p2). If p2≤0.05 then all doses significant. If p1≤0.025 then reject null for p1</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Model includes treatment, centre and baseline as a covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.3</ci_lower_limit>
            <ci_upper_limit>0.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Flibanserin 100 mg qhs versus placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0001</p_value>
            <p_value_desc>Hierarchical ordering used for multiple endpoints, and Hochberg used for multiple dose comparisons. P-values ordered (p1≤p2). If p2≤0.05 then all doses significant. If p1≤0.025 then reject null for p1</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Model includes treatment, centre and baseline as a covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.5</ci_lower_limit>
            <ci_upper_limit>-0.2</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Female Sexual Functioning Index (FSFI) Desire Domain Score Change From Baseline at Final Visit</title>
        <description>Female Sexual Function Inventory (FSFI) Desire Domain assesses sexual desire or interest with 2 questions ranging from 1 (very low) to 5 (very high). The domain total score is multiplied by 0.6 yielding scores ranging from 1.2 to 6 (higher scores = higher level of desire or interest).</description>
        <time_frame>Baseline, Week 24</time_frame>
        <population>The Full Analysis Set (FAS) consisted of those patients who were randomized to a treatment group, received at least one dose of study medication, and had at least one on-treatment efficacy assessment. The FAS was analyzed for efficacy.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>placebo at bedtime</description>
          </group>
          <group group_id="O2">
            <title>Flibanserin 50 mg q.h.s.</title>
            <description>Flibanserin 50 mg at bedtime</description>
          </group>
          <group group_id="O3">
            <title>Flibanserin 100 mg q.h.s</title>
            <description>Flibanserin 100 mg at bedtime</description>
          </group>
        </group_list>
        <measure>
          <title>Female Sexual Functioning Index (FSFI) Desire Domain Score Change From Baseline at Final Visit</title>
          <description>Female Sexual Function Inventory (FSFI) Desire Domain assesses sexual desire or interest with 2 questions ranging from 1 (very low) to 5 (very high). The domain total score is multiplied by 0.6 yielding scores ranging from 1.2 to 6 (higher scores = higher level of desire or interest).</description>
          <population>The Full Analysis Set (FAS) consisted of those patients who were randomized to a treatment group, received at least one dose of study medication, and had at least one on-treatment efficacy assessment. The FAS was analyzed for efficacy.</population>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="290"/>
                <count group_id="O2" value="293"/>
                <count group_id="O3" value="280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="0.1"/>
                    <measurement group_id="O2" value="0.8" spread="0.1"/>
                    <measurement group_id="O3" value="0.9" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Flibanserin 50 mg qhs versus placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0173</p_value>
            <method>ANCOVA</method>
            <method_desc>Model includes treatment, centre and baseline as a covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.0</ci_lower_limit>
            <ci_upper_limit>0.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Flibanserin 100 mg qhs versus placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>Model includes treatment, centre and baseline as a covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.2</ci_lower_limit>
            <ci_upper_limit>0.5</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Female Sexual Functioning Index (FSFI) Total Score Change From Baseline at Final Visit</title>
        <description>The FSFI© is a self-administered questionnaire to assess FSD, which consists of 19 questions that are scored from ‘0’ to ‘5.’ The scale contains six domains: desire, arousal, lubrication, orgasm, satisfaction, and pain. Higher scores indicate higher levels of the domain assessed. The total score is a weighted average of the six domains, each contributing a maximum of 6 points to the total, so the minimum score is 2, while the maximum score of FSFI© is 36.</description>
        <time_frame>Baseline, Week 24</time_frame>
        <population>The Full Analysis Set (FAS) consisted of those patients who were randomized to a treatment group, received at least one dose of study medication, and had at least one on-treatment efficacy assessment. The FAS was analyzed for efficacy.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>placebo at bedtime</description>
          </group>
          <group group_id="O2">
            <title>Flibanserin 50 mg q.h.s.</title>
            <description>Flibanserin 50 mg at bedtime</description>
          </group>
          <group group_id="O3">
            <title>Flibanserin 100 mg q.h.s</title>
            <description>Flibanserin 100 mg at bedtime</description>
          </group>
        </group_list>
        <measure>
          <title>Female Sexual Functioning Index (FSFI) Total Score Change From Baseline at Final Visit</title>
          <description>The FSFI© is a self-administered questionnaire to assess FSD, which consists of 19 questions that are scored from ‘0’ to ‘5.’ The scale contains six domains: desire, arousal, lubrication, orgasm, satisfaction, and pain. Higher scores indicate higher levels of the domain assessed. The total score is a weighted average of the six domains, each contributing a maximum of 6 points to the total, so the minimum score is 2, while the maximum score of FSFI© is 36.</description>
          <population>The Full Analysis Set (FAS) consisted of those patients who were randomized to a treatment group, received at least one dose of study medication, and had at least one on-treatment efficacy assessment. The FAS was analyzed for efficacy.</population>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="289"/>
                <count group_id="O2" value="292"/>
                <count group_id="O3" value="280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4" spread="0.4"/>
                    <measurement group_id="O2" value="3.9" spread="0.4"/>
                    <measurement group_id="O3" value="5.0" spread="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Flibanserin 50 mg qhs versus placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0071</p_value>
            <method>ANCOVA</method>
            <method_desc>Model includes treatment, centre and baseline as a covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.4</ci_lower_limit>
            <ci_upper_limit>2.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Flibanserin 100 mg qhs versus placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>Model includes treatment, centre and baseline as a covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.4</ci_lower_limit>
            <ci_upper_limit>3.6</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Benefit Evaluation</title>
        <description>The Patient Benefit Evaluation is a single question asking the patient whether or not she experienced a meaningful benefit from the study medication during the trial. This question (“Overall, do you believe that you have experienced a meaningful benefit from the study medication?”) was asked upon treatment discontinuation.</description>
        <time_frame>Week 24</time_frame>
        <population>This question was asked at Week 24 only, so did not include participants who had discontinued the trial prior to that time (e.g., analysis population includes treatment completers only).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>placebo at bedtime</description>
          </group>
          <group group_id="O2">
            <title>Flibanserin 50 mg q.h.s.</title>
            <description>Flibanserin 50 mg at bedtime</description>
          </group>
          <group group_id="O3">
            <title>Flibanserin 100 mg q.h.s</title>
            <description>Flibanserin 100 mg at bedtime</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Benefit Evaluation</title>
          <description>The Patient Benefit Evaluation is a single question asking the patient whether or not she experienced a meaningful benefit from the study medication during the trial. This question (“Overall, do you believe that you have experienced a meaningful benefit from the study medication?”) was asked upon treatment discontinuation.</description>
          <population>This question was asked at Week 24 only, so did not include participants who had discontinued the trial prior to that time (e.g., analysis population includes treatment completers only).</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="266"/>
                <count group_id="O2" value="271"/>
                <count group_id="O3" value="254"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Meaningful benefit from medication</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71"/>
                    <measurement group_id="O2" value="94"/>
                    <measurement group_id="O3" value="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No meaningful benefit from medication</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="195"/>
                    <measurement group_id="O2" value="177"/>
                    <measurement group_id="O3" value="156"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Flibanserin 25 mg bid versus placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0513</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Model includes treatment and centre</method_desc>
            <param_type>Percentage responders</param_type>
            <param_value>34.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>29.0</ci_lower_limit>
            <ci_upper_limit>40.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Flibanserin 50 mg qhs versus placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0059</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Model includes treatment and centre</method_desc>
            <param_type>Percentage responders</param_type>
            <param_value>38.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>32.6</ci_lower_limit>
            <ci_upper_limit>44.6</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>placebo at bedtime</description>
        </group>
        <group group_id="E2">
          <title>Flibanserin 50 mg q.h.s.</title>
          <description>Flibanserin 50 mg at bedtime</description>
        </group>
        <group group_id="E3">
          <title>Flibanserin 100 mg q.h.s</title>
          <description>Flibanserin 100 mg at bedtime</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA Version 11.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="295"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="290"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Crohn's disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="290"/>
              </event>
              <event>
                <sub_title>Large intestine perforation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="290"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="295"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="290"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="295"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="290"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="295"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="290"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Respiratory fume inhalation disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="290"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="290"/>
              </event>
              <event>
                <sub_title>Metastases to lymph nodes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="295"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="290"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA Version 11.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="87" subjects_at_risk="295"/>
                <counts group_id="E2" subjects_affected="107" subjects_at_risk="295"/>
                <counts group_id="E3" subjects_affected="135" subjects_at_risk="290"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="295"/>
                <counts group_id="E2" events="23" subjects_affected="23" subjects_at_risk="295"/>
                <counts group_id="E3" events="33" subjects_affected="33" subjects_at_risk="290"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="295"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="295"/>
                <counts group_id="E3" events="18" subjects_affected="18" subjects_at_risk="290"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="24" subjects_affected="24" subjects_at_risk="295"/>
                <counts group_id="E2" events="26" subjects_affected="26" subjects_at_risk="295"/>
                <counts group_id="E3" events="18" subjects_affected="18" subjects_at_risk="290"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="295"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="295"/>
                <counts group_id="E3" events="18" subjects_affected="18" subjects_at_risk="290"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="295"/>
                <counts group_id="E2" events="22" subjects_affected="22" subjects_at_risk="295"/>
                <counts group_id="E3" events="13" subjects_affected="13" subjects_at_risk="290"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="295"/>
                <counts group_id="E2" events="15" subjects_affected="15" subjects_at_risk="295"/>
                <counts group_id="E3" events="26" subjects_affected="26" subjects_at_risk="290"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="27" subjects_affected="27" subjects_at_risk="295"/>
                <counts group_id="E2" events="27" subjects_affected="22" subjects_at_risk="295"/>
                <counts group_id="E3" events="22" subjects_affected="22" subjects_at_risk="290"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="295"/>
                <counts group_id="E2" events="26" subjects_affected="26" subjects_at_risk="295"/>
                <counts group_id="E3" events="32" subjects_affected="32" subjects_at_risk="290"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="295"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="295"/>
                <counts group_id="E3" events="21" subjects_affected="21" subjects_at_risk="290"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Any publication of the result of this trial must be consistent with the Sprout Pharmaceuticals publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Sprout Pharmaceuticals</name_or_title>
      <organization>Sprout Pharmaceuticals</organization>
      <phone>1-919-882-0850</phone>
      <email>clinicaltrials@sproutpharma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

